Objectives
BARLOW
Edited by: Jan I. Olofsson, Karolinska Institutet (KI), SwedenReviewed by: Eric Kilpatrick, Sidra Medicine, Qatar; David Barlow, University of Glasgow, United Kingdom; Gehanath Baral, Nobel Medical College Teaching Hospital (NMCTH), NepalThe aim of the study was to investigate the effect of treatment on pregnancy outcomes among women who had fasting plasma glucose (FPG) 5.1-5.6 mmol/l in the first trimester of pregnancy.